DexCom Quarterly Income Statement

NASDAQ: DXCMHealth CareMedical/Dental InstrumentsUSD

84.11-0.30 (-0.36%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

DexCom revenue and earnings

In the quarter ended Jun 30, 2026, DexCom generated $1.31 billion in revenue, up 13.1% from the same quarter a year earlier. Net income was $249.1 million (+38.5% year over year), for a net margin of 19.0% versus a median of 16.7% in the prior 5 quarters. Gross margin was 63.4% (up from 59.5%) and operating margin 24.3%.

Diluted earnings per share came in at $0.64, up from $0.45.

Summary generated from market data by MetaCap's automated system. Methodology

DexCom income statement (quarterly)

DexCom quarterly income statement
Quarter (USD)	Q2 20262026-06-30	Q1 20262026-03-31	Q4 20252025-12-31	Q3 20252025-09-30	Q2 20252025-06-30	Q1 20252025-03-31	Q4 20242024-12-31	Q3 20242024-09-30	Q2 20242024-06-30	Q1 20242024-03-31	Q4 20232023-12-31	Q3 20232023-09-30
Revenue	1.31B	1.19B	1.26B	1.21B	1.16B	1.04B	1.11B	994.20M	1.00B	921.00M	1.03B	975.00M
Revenue growth (YoY)	+13.08%	+15.05%	+13.12%	+21.64%	+15.21%	+12.49%	+7.64%	+1.97%	+15.26%	+24.21%	+26.90%	+26.69%
Cost of Revenue	478.40M	441.60M	466.90M	477.90M	468.30M	447.00M	457.70M	400.40M	377.60M	359.10M	377.90M	351.70M
Gross Profit	830.00M	750.30M	792.70M	731.40M	688.80M	589.00M	655.80M	593.80M	626.70M	561.90M	656.60M	623.30M
Operating Expenses	511.70M	495.00M	469.70M	488.90M	476.20M	455.30M	466.90M	441.80M	468.70M	460.80M	439.70M	417.80M
Research & Development	153.00M	145.30M	148.20M	157.50M	148.20M	145.20M	139.50M	135.40M	136.00M	141.50M	136.10M	131.40M
Selling, General & Admin	358.70M	349.70M	321.50M	331.40M	328.00M	310.10M	327.40M	306.40M	332.70M	319.30M	303.60M	286.40M
Operating Income	318.30M	255.30M	323.00M	242.50M	212.60M	133.70M	188.90M	152.00M	158.00M	101.10M	216.90M	205.50M
Interest Expense	3.00M	3.10M	4.20M	4.70M	4.70M	4.70M	4.90M	4.70M	4.80M	4.60M	4.90M	4.90M
Other Income (Expense)	-800.00K	14.20M	17.70M	109.80M	28.50M	20.60M	22.40M	25.40M	29.80M	31.40M	29.30M	34.90M
Pretax Income	317.50M	269.50M	340.70M	352.30M	241.10M	154.30M	211.30M	177.40M	187.80M	132.50M	246.20M	240.40M
Income Tax	68.40M	70.00M	73.40M	68.50M	61.30M	48.90M	59.60M	42.80M	44.30M	-13.90M	-10.10M	119.70M
Net Income	249.10M	199.50M	267.30M	283.80M	179.80M	105.40M	151.70M	134.60M	143.50M	146.40M	256.30M	120.70M
Net Income growth (YoY)	+38.54%	+89.28%	+76.20%	+110.85%	+25.30%	-28.01%	-40.81%	+11.52%	+23.81%	+201.23%	+179.19%	+19.27%
EPS (Basic)	0.65	0.52	0.68	0.73	0.46	0.27	0.38	0.34	0.36	0.38	0.66	0.31
EPS (Diluted)	0.64	0.51	0.67	0.70	0.45	0.27	0.37	0.34	0.35	0.36	0.61	0.29
Shares Outstanding (Basic)	382.20M	385.10M	—	391.10M	392.10M	391.10M	—	394.20M	399.20M	390.20M	—	386.60M
Shares Outstanding (Diluted)	390.10M	393.60M	—	407.40M	408.20M	407.50M	—	410.20M	416.80M	416.70M	—	426.80M
EBITDA	386.50M	322.40M	388.20M	306.10M	275.60M	193.70M	246.70M	207.30M	210.10M	153.60M	269.40M	253.70M
Gross Margin	63.44%	62.95%	62.93%	60.48%	59.53%	56.85%	58.90%	59.73%	62.40%	61.01%	63.47%	63.93%
Operating Margin	24.33%	21.42%	25.64%	20.05%	18.37%	12.91%	16.96%	15.29%	15.73%	10.98%	20.97%	21.08%
Net Margin	19.04%	16.74%	21.22%	23.47%	15.54%	10.17%	13.62%	13.54%	14.29%	15.90%	24.78%	12.38%

This table shows 12 quarterly periods of DexCom's income statement, from Q2 2026 back to Q3 2023, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow DXCM's reporting calendar. What is a income statement?